Trontinemab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | RG6102 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Trontinemab (RG6102) is a monoclonal antibody developed by Roche/Genentech for the treatment of Alzheimer's disease. It is based on gantenerumab, an anti-amyloid monoclonal antibody, and uses a Brainshuttle domain to enhance its permeability through the blood-brain barrier. Compared to gantenerumab, it has 50 times as much penetrance into the brain.